20197-96-0

Basic information

• Product Name: 2,7-DICHLOROQUINAZOLIN-4(3H)-ONE
• Synonyms: 2,7-DICHLOROQUINAZOLIN-4(3H)-ONE
• CAS NO: 20197-96-0
• Molecular Formula: C₈H₄Cl₂N₂O
• Molecular Weight: 215.04
• Mol File: 20197-96-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 353.1±44.0 °C(Predicted)
• Appearance: /
• Density: 1.65±0.1 g/cm3(Predicted)
• PKA: -4.45±0.20(Predicted)
• CAS DataBase Reference: 2,7-DICHLOROQUINAZOLIN-4(3H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,7-DICHLOROQUINAZOLIN-4(3H)-ONE(20197-96-0)
• EPA Substance Registry System: 2,7-DICHLOROQUINAZOLIN-4(3H)-ONE(20197-96-0)

Safety Data

• Hazardous Substances Data: 20197-96-0(Hazardous Substances Data)

Usage

Type of compound

Heterocyclic compound

Contains

Chlorine atoms

Function

Quinazolinone derivative

Used in

Synthesis of pharmaceuticals and agrochemicals

Potential

Building block for novel compounds with biological activities (e.g. anti-inflammatory and antimicrobial properties)

Studied for

Potential as herbicide and fungicide

Versatility

Holds promise for a range of applications in medicine and agriculture.

Upstream product

• 6625-94-1 2,4,7-trichloroquinazoline 
• 13165-35-0 7-chloroquinazoline-2,4-dione 
• 89-77-0 2-Amino-4-chlorobenzoic acid 

Downstream Products

• 105150-91-2 7-Chloro-2-[3-(3-piperidin-1-ylmethyl-phenoxy)-propylamino]-3H-quinazolin-4-one 
• 769158-10-3 2-((2,7-dichloro-4-oxoquinazolin-3(4H)-yl)methyl)benzonitrile 

Relevant articles and documents

Synthesis and biological evaluation of 2-benzylaminoquinazolin-4(3H)-one derivatives as a potential treatment for SARS-CoV-2

Despite the continuing global crisis caused by coronavirus disease 2019 (COVID-19), there is still no effective treatment. Therefore, we designed and synthesized a novel series of 2-benzylaminoquinazolin-4(3H)-one derivatives and demonstrated that they ar

DIACYLGLYCEROL KINASE MODULATING COMPOUNDS

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

Discovery of alogliptin: A potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). Herein, we describe the structure-based design and optimization of alogliptin and related quinazolinone-based DPP-4 inhibitors. Following an oral dose, these noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and a lowering of blood glucose in animal models of diabetes. Alogliptin is currently undergoing phase 111 trials in patients with type 2 diabetes.